1. Home
  2. SCLX vs PMVP Comparison

SCLX vs PMVP Comparison

Compare SCLX & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$6.79

Market Cap

55.1M

Sector

Health Care

ML Signal

HOLD

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.11

Market Cap

66.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCLX
PMVP
Founded
2011
2013
Country
United States
United States
Employees
34
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.1M
66.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SCLX
PMVP
Price
$6.79
$1.11
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
119.0K
297.8K
Earning Date
04-10-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$122.52
N/A
Revenue Next Year
$186.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.20
$1.02
52 Week High
$34.27
$1.88

Technical Indicators

Market Signals
Indicator
SCLX
PMVP
Relative Strength Index (RSI) 39.46 36.48
Support Level $5.72 N/A
Resistance Level $7.77 $1.26
Average True Range (ATR) 0.79 0.09
MACD -0.26 -0.03
Stochastic Oscillator 0.27 2.56

Price Performance

Historical Comparison
SCLX
PMVP

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: